IBt Bebig presents its new HDRplus 3.0 at ESTRO
0
IBt Bebig presents its new HDRplusTM 3.0 at ESTRO
May 10, 2011
Seneffe - Belgium, May 10, 2011, IBt Bebig (Reuters: IBTH.BR - Bloomberg: IBTB
BB) has announced today that it releases its new version of the treatment
planning HDRplusTM 3.0 at the ESTRO International Oncology Forum held in London
on May 8-12, 2011.
The HDRplus(TM) is an innovative software program for precise and efficient HDR
(High Dose Rate) treatment planning. It provides its users with functions that
considerably simplify and speed up their plan preparation. The software delivers
an optimized treatment plan and makes the process especially fast, flexible and
precise. The user interface features a modern and easy-to-use structure,
including many possibilities to customize the layout and parameter settings.
This allows the user to tailor the system to his own workflow.
HDRplus(TM) software supports all HDR applications, including intraluminal,
interstitial, intracavitary, intra-operative und surface mould treatments. An
optional Prostate Module permits real time online planning using transversal and
longitudinal TRUS (Transrectal Ultrasonography). HDRplus(TM) has a complete
applicator database which shortens the work flow and minimizes possibilities of
human errors.
Further functionalities have been implemented in version 3.0 of HDRplus(TM) in
order to speed up the treatment planning process: Automatic catheter tracking
and automatic image fusion of different image modalities like US (Ultrasound
Imaging), CT (Computed Tomography), MRI (Magnetic Resonance Imaging) and PET
(Positron Emission Tomography) are now supported. Improved DICOM 3 and DICOM RT
network functionality offers the customer to share the information with other
systems.
"IBt Bebig continues to innovate in the world of Brachytherapy as our goal is to
bring the most efficient products for the benefits of patients and medical
practitioners. We are proud to be the first company in the world to release a
software calculating biological effective doses for the combined treatment of
EBRT (External Beam Radio Therapy) and Brachytherapy. Our new HDRplus(TM) offers
also the Automatic Image Fusion that enables users to match CT and MR images
without any necessary interaction in less than 30 seconds", said Dr. Edgar
Löffler, Managing Director of IBt Bebig. "We react on the current market needs
and we support other vendor of afterloader system protocols as well with our new
software. This allows for further market expansion".
About IBt Bebig
...Contributing to saving lives!
IBt Bebig is a European-based group active in the medical device sector of the
health care industry.
Its core business is the treatment of cancer by brachytherapy, a special form of
radiotherapy. IBt Bebig is a leader in brachytherapy in Europe and is
headquartered in Belgium. It has a production facility in Germany and
subsidiaries throughout Europe, as well as in India. IBt Bebig has also
established a worldwide network of distributors and agents to support its
product line.
The company´s products and equipment are intended for use by oncologists,
radiologists, urologists, and medical physicists.
IBt Bebig employs more than 150 people. It has been listed on the Euronext stock
exchange since April 1997 (Reuters: IBTH.BR - Bloomberg: IBTB BB).
Contact
Paul-Emmanuel Goethals
Investor Relations
Tel: +32.64.520.808
E-mail:ir@ibt-bebig.eu
Internet:www.ibt-bebig.eu
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: IBt Bebig via Thomson Reuters ONE
[HUG#1514284]
BE0003689032
